273 related articles for article (PubMed ID: 28857713)
1. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
Dranitsaris G; Shane LG; Woodruff S
J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
[TBL] [Abstract][Full Text] [Related]
2. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
3. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
[TBL] [Abstract][Full Text] [Related]
4. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Dranitsaris G; Shane L; Burgers L; Woodruff S
Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
6. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
J Exp Clin Cancer Res; 2008 Jul; 27(1):21. PubMed ID: 18634550
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
9. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Lopez LM
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):56S-61S; discussion 71S-72S. PubMed ID: 11401194
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
13. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
Dranitsaris G; Shane LG; Crowther M; Feugere G; Woodruff S
Clinicoecon Outcomes Res; 2017; 9():65-73. PubMed ID: 28138260
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
Dranitsaris G; Vincent M; Crowther M
Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
[TBL] [Abstract][Full Text] [Related]
15. Management of recurrent venous thromboembolism in cancer patients.
Romualdi E; Ageno W
Thromb Res; 2016 Apr; 140 Suppl 1():S128-31. PubMed ID: 27067966
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients.
Dooley C; Kaur R; Sobieraj DM
Curr Med Res Opin; 2014 Mar; 30(3):367-80. PubMed ID: 23971722
[TBL] [Abstract][Full Text] [Related]
18. [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].
Debourdeau P; Cossou-Gbeto C; Takam-Sohwe T; Laroche JP
Bull Cancer; 2020 Feb; 107(2):224-233. PubMed ID: 32005356
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
20. Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review.
Thirugnanam S; Pinto R; Cook DJ; Geerts WH; Fowler RA
Crit Care; 2012 Mar; 16(2):R43. PubMed ID: 25927574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
